Board, Staff & Committees
CGPA Board of Directors
| Barry Fishman, Chair |
Teva |
| Luciano Calenti |
ACIC |
| Jack Kay |
Apotex |
| Jeff Watson |
Apotex |
| Ian Jacobson |
Cobalt |
| David Goodman |
Pharmascience |
| Mario Deschamps |
Pharmascience |
| Morris Goodman |
Pharmascience |
| Paul Drake |
Ranbaxy |
| Jean-Guy Goulet |
ratiopharm |
| Murray Roach |
Taro |
| |
| CGPA Staff |
|
| |
| Jim Keon, President |
jim@canadiangenerics.ca |
| Jeff Connell, Director of Public Affairs |
jeff@canadiangenerics.ca |
| Jessie Pushell, Executive Assistant |
jessie@canadiangenerics.ca |
| Jody Cox, Director of Federal Government Relations |
jody@canadiangenerics.ca |
| Julie Tam, Vice-President Professional & Scientific Affairs |
julie@canadiangenerics.ca |
| Paula Rembach, Research Analyst |
paula@canadiangenerics.ca |
| Theresa Elmido, Receptionist / Administrator |
theresa@canadiangenerics.ca |
| Yves Dupré, Executive Director - Quebec |
yves@canadiangenerics.ca |
| Ed Hore, Legal Counsel |
|
Committees
Scientific Affairs Committee
This committee is responsible for liaising with, and providing input to, Health Canada on various scientific issues related to the approval of generic pharmaceuticals at the federal level.
Chair: John Hems, Apotex
Vice-Chair: Len Arsenault, Sandoz
Provincial Regulatory Committee
This committee is responsible for working with provincial health ministries on regulatory issues related to the listing of generic drugs on provincial drug plan formularies.
Chair: Hana Nosseir, Pharmascience
Vice-Chair: Houri Ohan, Teva
Bioequivalence Committee
This committee provides scientific advice in dealing with bioequivalence and interchangeability issues. This committee regularly interacts with Health Canada and its expert working group on Bioequivalence.
Chair: Yu Chung Tsang, Apotex
Government Affairs Committee
The committee assists CGPA in its communications with all levels of government.
Chair: Terry Creighton, Teva
Vice-Chair: Elie Betito, Apotex
Intellectual Property Committee
This committee provides advice to CGPA on issues related to Canada’s pharmaceutical patent regime.
Chair: Ildiko Mehes, Teva
Vice-Chair: Scott Beeser, Apotex
Market Growth Committee
This committee develops strategies to facilitate the increase in generic pharmaceutical sales in Canada and internationally. This group benchmarks international practices and develops options for companies to increase private sector market share.
Industry Practices Review Board - National
This board is responsible for the education, compliance and enforcement activities required for the implementation of CGPA's code of marketing conduct on a national basis.
Biosimilar Steering Group
This steering group provides leadership and expert advice on all aspects of biosimilar medicines, which are known as subsequent entry biologics (SEBs) in Canada. This includes liaising with Health Canada as it develops and implements an abbreviated pathway for the timely approval of safe and effective subsequent entry biologics.
TOP
